A systematic literature review of the diagnosis of drug resistant tuberculosis using Xpert MTB/RIF assay and its potential impacts on treatment outcomes

Authors

  • Samorn Numpong The Office of Disease Prevention and Control region 9, Nakhon Ratchasima
  • Yada Toutchon The Office of Disease Prevention and Control region 9, Nakhon Ratchasima
  • Wiwat Sungkhabut The Office of Disease Prevention and Control region 9, Nakhon Ratchasima

DOI:

https://doi.org/10.14456/dcj.2020.29

Keywords:

Diagnosis, Drug Resistant Tuberculosis, Impacts

Abstract

The World Health Organization (WHO) reported that the treatment success rate of rifampicin resistant tuberculosis and multidrug resistant tuberculosis (MDR-TB) was 55.00%. Approximately 8.50% of MDR-TB eventually developed extensively drug resistant tuberculosis (XRD-TB). Early detection of TB among high-risk groups by molecular method was one among many strategies of Thailand Operational Plan to End Tuberculosis 2017-2021. The Xpert MTB/RIF assay was therefore implemented around 3-4 years ago to speed up the diagnosis of RR TB but the studies on the impacts of Xpert MTB/RIF assay on treatment outcomes were limited. The study aimed to compare time to detect DR-TB, time to initiate treatment, and time to have sputum culture conversion between patients who were diagnosed with DR-TB by Xpert MTB/RIF assay and conventional gold standard method currently used in Thailand. A systematic literature review and meta-analysis were conducted for the study. A total of 299 articles published locally and internationally from 2010 to 2017 were identified, seven of which were found to meet the study objectives. Based on the data analysis, Xpert MTB/RIF assay was found to have shortened time to detect DR-TB, time to initiate treatment, and time to obtain sputum culture conversion, taking 34.30-91.50 days, 61-62 days, and 134.50 days, respectively. Successful treatment and unfavorable outcomes were not significantly different between two groups (RR = 0.95, 95% CI: 0.47-1.91; random-effect model, I-squared (I2) = 75%) and (RR = 0.81, 95% CI: 0.44-1.50; random-effect model, I-squared = 54%). I2 showed heterogeneity between two groups so that the cause of differences could not definitely determined. In conclusion, Xpert MTB/RIF assay could shorten the time to diagnose RR TB; time to initiate treatment was also faster; and time to obtain sputum culture conversion was shorter. However, the final impact on outcome was not clearly demonstrated.

References

World Health Organization. Global Tuberculosis Report 2017 [Internet]. Switzerland. 2017 Oct [cited 2019 Jan 14]. 249 p. Available from: https://www.who.int/tb/areas-of-work/drug-resistant-tb/en/

World Health Organization. Xpert MTB/RIF implementtation manual, technical and operation ‘how-to’: practical considerations [Internet]. France. 2013 May [cited 2019 Jan 16]. 42 p. Available from: www.who.int

Nestani Tukvadze. RRK, Iagor Kalandadze, Ekaterina Kurbatova, Michael K.Leonard, Rusudan Apsindzelashvili, Nino Bablishvili, et al. Use of a Molecular Diagnostic Test in AFB Smear Positive Tuberculosis Suspects Greatly Reduces Time to Detection of Multidrug Resistant Tuberculosis. Plos one [Internet]. 2012 [cited 2018 Oct 3 ];7: e31563. Available from: https://www-ncbi-nlm-nih-gov.ejournal.mahidol.ac.th/

Maia Kipiani VM, Nestani Tukvadze, Matthew Magee, Henry M. Blumberg and Russell R. Kempker. Significant Clinical Impact of a Rapid Molecular Diagnostic Test (Genotype MTBDRplus Assay) to Detect Multidrug-Resistant Tuberculosis. Oxford Journal [Internet]. 2014 [cited 2018 Oct 3];59: 1559-66. Available from: https://www-ncbi-nlm-nih-gov.ejournal.mahidol.ac.th/

Eliseev P, Balantcev G, Nikishova E, Gaida A, Bogdanova E, Enarson D, et al. The Impact of a Line Probe Assay Based Diagnostic Algorithm on Time to Treatment Initiation and Treatment Outcomes for Multidrug Resistant TB Patients in Arkhangelsk Region, Russia. PLoS ONE [Internet]. 2016 [cited 2018 Oct 3];11: 1-13. Available from: https://www-ncbi-nlm-nih-gov.ejournal.mahidol.ac.th/

Colleen F. Hanrahan SED, Linda Erasmus, Hendrik Koornhof, Gerrit Coetzee,Jonathan E. Golub. The Impact of Expanded Testing for Multidrug Resistant Tuberculosis Using Geontype MTBDR An Observational Cohort Study. Plos one [Internet]. 2012 [cited 2018 Oct 6];8: e49898. Available from: https://journals.plos.org/

Aibana O, Bachmaha M, Krasiuk V, Rybak N, Flanigan TP, Petrenko V, et al. Risk factors for poor multidrug-resistant tuberculosis treatment outcomes in Kyiv Oblast, Ukraine. BMC infect Dis [Internet]. 2017 [cited 2018 Oct 10];17:1-7. Available from: https://bmcinfectdis.biomedcentral.com/articles/

Metcalfe JZ, Makumbirofa S, Makamure B, Sandy C, Bara W, Mason P, et al. Xpert((R)) MTB/RIF detection of rifampin resistance and time to treatment initiation in Harare, Zimbabwe. Int J Tuberc Lung Dis [Internet]. 2016 [cited 2018 Oct 10];20:882-9. Available from: https://www-ncbi-nlm-nih-gov.ejournal.mahidol.ac.th/pubmed

Cox H, Dickson-Hall L, Ndjeka N, van’t Hoog A, Grant A, Cobelens F, et al. Delays and loss to follow-up before treatment of drug-resistant tuberculosis following implementation of Xpert MTB/RIF in South Africa: A retrospective cohort study. PLoS Med [Internet]. 2017 [cited 2018 Oct 15];14: 1-19. Available from: https://www-scopus.com. ejournal.mahidol.ac.th

Jacobson KR, Barnard M, Kleinman MB, Streicher EM, Ragan EJ, White LF, et al. Implications of failure to routinely diagnose resistance to second-line drugs in patients with rifampicin-resistant tuberculosis on Xpert MTB/RIF: A multisite observational study. Clin Infect Dis [Internet]. 2017 [cited 2018 Oct 20];64: 1502-8. Available from: https://www-scopus-com.ejournal.mahidol.ac.th/

Kim YW, Seong MW, Kim TS, Yoo CG, Kim YW, Han SK, et al. Evaluation of Xpert® MTB/RIF assay: Diagnosis and treatment outcomes in rifampicin-resistant tuberculosis. Int J Tuberc Lung Dis. [Internet]. 2015 [cited 2018 Nov 2];19: 1216-21. Available from: https://www-ncbi-nlm-nih-gov.ejournal.mahidol.ac.th/pubmed

Liu Z, Pan A, Wu B, Zhou L, He H, Meng Q, et al. Feasibility of a new model for early detection of patients with multidrug-resistant tuberculosis in a developed setting of eastern China. Trop Med Inter Health. [Internet]. 2017 [cited 2018 Nov 5] ;22: 1328-33. Available from: https://www-scopus-com.ejournal.mahidol.ac.th/

Guideline for Programmatic Management of Drug-Resistant Tuberculosis). Nonthaburi: Bureau of Tuberculosis; 2558. (in Thai)

Berhanu R, Schnippel K, Mohr E, Hirasen K, Evans D, Rosen S, et al. Early outcomes of decentralized care for rifampicin-resistant tuberculosis in Johannesburg, South Africa: An observational cohort study. PLoS ONE [Internet]. 2016 [cited 2018 Nov 8];11: 1-14. Available from: https://www-scopus-com.ejournal.mahidol.ac.th/

Yihunie Akalu T, Muchie KF, Alemu Gelaye K. Time to sputum culture conversion and its determinants among Multi-drug resistant Tuberculosis patients at public hospitals of the Amhara Regional State: A multicenter retrospective follow up study. PLoS One [Internet]. 2018 [cited 2018 Nov 15];13: e0199320. Available from: https://journals.plos.org/

Shibabaw A, Gelaw B, Wang SH, Tessema B. Time to sputum smear and culture conversions in multidrug resistant tuberculosis at University of Gondar Hospital, Northwest Ethiopia. PLoS One [Internet]. 2018 [cited 2108 Dec 2];13: e0198080. Available from: https://journals.plos.org/

Boyd R, Ford N, Padgen P, Cox H. Time to treatment for rifampicin-resistant tuberculosis: Systematic review and meta-analysis. Int J Tuberc Lung Dis. [Internet]. 2017 [cited 2018 Nov 20];21:1173-80. Available from: https://www-scopus-com.ejournal.mahidol.ac.th/

Evans CA. GeneXpert—A Game-Changer for Tuberculosis Control? PLOS Medicine [Internet]. 2011 [cited 2018 Nov 26];8: e1001064. Available from: https://journals.plos.org/

Downloads

Published

2020-09-29

How to Cite

1.
Numpong S, Toutchon Y, Sungkhabut W. A systematic literature review of the diagnosis of drug resistant tuberculosis using Xpert MTB/RIF assay and its potential impacts on treatment outcomes. Dis Control J [Internet]. 2020 Sep. 29 [cited 2024 Apr. 26];46(3):303-12. Available from: https://he01.tci-thaijo.org/index.php/DCJ/article/view/216821

Issue

Vol. 46 No. 3 (2020): July-September

Section

Original Article

License

Articles published in the Disease Control Journal are considered as academic work, research or analysis of the personal opinion of the authors, not the opinion of the Thailand Department of Disease Control or editorial team. The authors must be responsible for their articles.